


SYNTHESIS OF 1,2,3,4,4a,5,10,10a-OCTAHYDRO-7-HYDROXY-2,4a,5-TRIMETHYL-
1,5-ETHANOBENZO[g]QUINOLINE: BRIDGED BENZOMORPHAN WITH ANTAGONIST ACTIVITY

Mikio Hori*, Tadashi Kataoka, Hiroshi Shimizu, Eiji Imai, and Norihiro Kawamura
Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502, Japan

Abstract— A synthetic approach has been made for the synthesis of 1,5-ethano-
benzo[g]quinolines from 11-substituted 2,6-methano-3-benzazocine. The product
showed strong antagonist activity.

Although many reports appeared for the explanation of structure-activity relationships of
opiates,¹ those of antagonist activity were only a few. Recently Snyder et al.² and Kolb³
reported the importance of orientation of N-substituents (or lone-pair electrons) for both of
agonist and antagonist activities. But the directions of N-substituents in their hypotheses were
completely opposite each other. In line with our previous report of synthesis and activities of
1,3-bridged 2,6-methano-3-benzazocines,⁴ we report here the synthesis of the title compound,
namely 3,11-bridged 2,6-methano-3-benzazocine.

The synthesis of 1,5-ethanobenzo[g]quinoline skeleton (1) from 1-(substituted allyl)-1,2,5,6-
tetrahydro-2-benzylpyridines was reported by Kimura et al. in 1975.⁵ But the synthetic route
including double cyclizations had some limitations for the substituents such that C-4 methyl
group in compound 1 was indispensable. So we had to explore more general ones. We selected



title compound 3 as target molecule and the synthetic routes were considered. Recently, Michne et al.⁶ reported the synthesis of 11-substituted 2,6-methano-3-benzazocine (4). Therefore we chose the compound 4 as starting material and the ring D formation was investigated. As von Brown reaction of 4 resulted in extensive decomposition, protection of carbonyl group was required. The ketal (5) was obtained from 4 in 93 % yield. Von Brown reaction of 5 with BrCN in CHCl₃ gave N-CN derivative (6) followed by the reduction with LiAlH₄ to afford 7 (80.2 % yield from 5). Deketalization of 7 was achieved with dil. HCl to give N-demethylated product 8 in 95.5 % yield. Cyclizaion of 8 was performed with excess p-TsOH in refluxing toluene. In the NMR spectrum of the reaction mixture, broad signal at 5.75 ppm was assigned to the C-3 proton of enamine part. Subsequent hydrogenation over palladium in DMF afforded single product (2) in 30.4 % yield. The structure of 2 was proved to be 3,11-bridged 2,6-methano-3-benzazocine from elemental analysis, the mass and NMR spectra. The conformation of piperidine ring (ring C) of 2 was established to be chair form judging from the similar chemical shifts of C-4a and C-5 methyl groups with corresponding 2,6-methano-3-benzazocines. On the other hand, the stereochemistry of C-2 methyl group was speculated by the reports that C-11 methylene⁷ and C-1 carbonyl⁸ groups of 2,6-methano-3-benzazocines were reduced stereoselectively with H₂ over palladium in acidic media to give derivatives having beta methyl and beta hydroxyl groups, respectively. It is reasonable that the hydrogenation of enamine double bond of 9 occurred from less hindered side to give equatorial C-2 methyl substituent.⁹ Demethylation of 2 with BBr₃ in CHCl₃ gave phenol derivative 3 in 74.5 % yield.

The analgesic activities of 3 was weak but antagonist activity was strong.¹⁰

EXPERIMENTAL

Melting points were taken on a Yanagimoto micro melting point apparatus and are uncorrected. IR spectra were measured on a JASCO IR A-1 spectrometer. ¹H-NMR spectra were recorded on a Hitachi R-20B spectrometer with Me₄Si as an internal standard. Mass spectra (MS) were determined using JEOL D-300 mass spectrometer at 70 eV by a direct inlet.

Preparation of 1,2,3,4,5,6-Hexahydro-8-methoxy-3,6,11-trimethyl-11-(3,3-ethylenedioxybutano)-2,6-methano-3-benzazocine (5) — A mixture of 4⁶ HCl (162 mg) and ethylene glycol (0.5 g) was refluxed in 10 ml of benzene for 2 h and cooled. 10 % K₂CO₃ soln was added and extracted with ether, dried (K₂CO₃) and the solvent was evaporated off to give 173 mg (yield 93 %) of 5 as an oil. NMR (CDCl₃) δ 0.78 (3H, s, 11-CH₃), 1.28 (3H, s, 6-CH₃), 1.38 (3H, s, CH₃C(O)₂), 2.23 (3H, s, N-CH₃), 3.73 (3H, s, OCH₃), 3.93 (4H, s, OCH₂CH₂O), 6.52-7.08 (3H, m, arom H); MS, m/e 359 (M⁺), 272. Picrate was obtained as yellow prisms (EtOH); mp 206-210°C. Anal. Calcd for C₂₂H₃₃N₃O₃·C₆H₃N₃O₇: C, 57.14; H, 6.16; N, 9.52. Found: C, 57.01; H, 5.93; N, 10.14.

Preparation of 6.—A mixture of 5 (1.848 g) and BrCN (3.6 g) in 50 ml of CHCl_3 was refluxed for 1 h. After the solvent was evaporated off, the residue was purified by short silica-gel column chromatography using ether as an eluent to give pure 6 as a colorless powder; yield 1.736 g (80.2 %); NMR (CDCl_3) δ 0.78 (3H, s, 11- CH_3), 1.25 (3H, s, 6- CH_3), 1.38 (3H, s, $\text{CH}_3(\text{O})_2$), 3.75 (3H, s, OCH_3), 3.96 (4H, s, $\text{OCH}_2\text{CH}_2\text{O}$), 6.55-7.20 (3H, m, arom H); MS m/e 327, 370 (M^+); IR (KBr) ν cm^{-1} 2200 (CN).

Preparation of 7.—A mixture of 6 (1.736 g) and LiAlH_4 (841 mg) in 87 ml of THF was refluxed for 3 h and cooled. The reaction mixture was poured into a mixture of AcOEt and 10 % of aqueous K_2CO_3 and then extracted with ether. The organic layer was dried over K_2CO_3 and evaporated in vacuo to give 7 as an oil. NMR (CDCl_3) δ 0.78 (3H, s, 11- CH_3), 1.28 (3H, s, 6- CH_3), 1.39 (3H, s, $\text{CH}_3\text{C}(\text{O})_2$), 3.78 (3H, s, OCH_3), 3.94 (4H, s, $\text{OCH}_2\text{CH}_2\text{O}$), 6.52-7.08 (3H, m, arom H); MS m/e 300, 345 (M^+). IR ν cm^{-1} 2210 (CN).

Preparation of 8.—Compound 7 was stirred in 10% HCl (40 ml) at 50-60°C for 1 h. The solution was neutralized with K_2CO_3 and extracted with CHCl_3 . The organic layer was dried (K_2CO_3) and evaporated in vacuo to give 8 as an oil; yield 1.347 g (95.5 %); NMR (CDCl_3) δ 0.78 (3H, s, 2- CH_3), 1.32 (3H, s, 6- CH_3), 2.18 (3H, s, COCH_3), 3.77 (3H, s, OCH_3), 6.55-7.10 (3H, m, arom H); MS m/e 301 (M^+).

Preparation of 1,2,3,4,4a,5,10,10a-Octahydro-7-methoxy-2,4a,5-trimethyl-1,5-ethanobenzo[g]quinoline (2).—A mixture of 8 (389 mg) and *p*-toluenesulfonic acid monohydrate (272.3 mg) in

toluene (30 ml) was refluxed for 1 h. After the solvent was evaporated off, NMR spectrum of the residue was measured. NMR of 9 (CDCl_3) δ 0.87 (3H, s, 4a- CH_3), 1.35 (3H, s, 5- CH_3), 2.05 (3H, bs, 2- CH_3), 3.78 (3H, s, CH_3O), 5.75 (1H, br, 3-H), 6.6-7.1 (3H, m, arom H).

To the residue, 10% Pd-C (350 mg) and DMF (17.5 ml) were added. The mixture was hydrogenated for 12 h at rt. After the solvent was evaporated off, the residue was extracted with CH_2Cl_2 and dried over K_2CO_3 and evaporated in vacuo to give a crude oil (190 mg), which was chromatographed on silica-gel (using ether-hexane- Et_3N = 2:8:1 as eluent) to give 112 mg of 2 as a colorless powder; yield 30.4 % mp 90-93°C; NMR (CDCl_3) δ 0.68 (3H, s, 4a- CH_3), 1.18 (3H, d, 2- CH_3 , J=7.0 Hz), 1.32 (3H, s, 5- CH_3), 3.76 (3H, s, OCH_3), 6.55-7.11 (3H, m, arom H). MS m/e 285 (M^+).

Hydrobromide of 2 was obtained as colorless prisms (EtOH); mp 270 °C. Anal. Calcd for $\text{C}_{19}\text{H}_{27}\text{NO}$ ·HBr: C, 62.29; H, 7.70; N, 3.82. Found: C, 62.04; H, 7.79; N, 3.77.

Preparation of 3.—To a solution of BBr_3 (0.3 g) in CHCl_3 (3 ml) was added 2 (24 mg) in CHCl_3 (3 ml) at 0°C. After stirring for 0.5 h, the reaction mixture was poured into ice- NH_4OH mixture and extracted with CHCl_3 . The CHCl_3 solution was dried over MgSO_4 and evaporated in vacuo to give 17 mg of crystals (yield 74.5 %). NMR (CDCl_3) δ 0.72 (3H, s, 4a- CH_3), 1.19 (3H, d, 2- CH_3 , J=7.0 Hz), 1.30 (3H, s, 5- CH_3), 6.40-7.05 (3H, m, arom H); MS m/e 271 (M^+). 3-hydrochloride;

colorless needles (MeOH-AcOEt), mp > 300°C. Anal. Calcd for $C_{18}H_{25}NO \cdot HCl \cdot 1/2H_2O$; C, 68.21; H, 8.59; N, 4.42. Found; C, 68.44; H, 8.54; N, 4.36.

REFERENCES AND NOTES

1. Receptor models; Distances between phenyl and proton on nitrogen; T. G. Cochran, J. Med. Chem., 1974, 17, 987. Distances between phenyl and N^+ ; K. F. Opheim and B. M. Cox, J. Med. Chem., 1976, 19, 857. P. W. Shiller, C. F. Yam, and M. Lis, Biochemistry, 1977, 16, 1831. cf. S. Shiotani, T. Kometani, Y. Iitaka, and A. Itai, J. Med. Chem., 1978, 21, 153.
2. A. P. Feinberg, I. G. Creese, and S. H. Snyder, Pro. Natl. Acad. Sci. USA, 1976, 73, 4215.
3. V. M. Kolb, J. Pharm. Sci., 1978, 67, 999.
4. M. Hori, T. Kataoka, H. Shimizu, E. Imai, Y. Suzuki, N. Kawamura, H. Fujimura, M. Nozaki, and M. Niwa, Chem. Pharm. Bull., 1983, 31, 2520; M. Hori, T. Kataoka, H. Shimizu, E. Imai, Y. Suzuki, and N. Kawamura, Heterocycles, 1983, 20, 1979.
5. a) M. Kimura, T. Nakajima, T. Atsumi, Y. Koga, and H. Yamamoto, Chem. Pharm. Bull., 1975, 23, 3208. b) M. Kimura, T. Nakajima, S. Inaba, and H. Yamamoto, Bull. Chem. Soc. Japan, 1974, 47, 1404.
6. W. F. Michne, T. R. Lewis, S. J. Michalec, A. K. Pierson, and F. J. Rosenberg, J. Med. Chem., 1979, 22, 1158.
7. C. F. Chignell and E. L. May, J. Med. Chem., 1965, 8, 385; S. Saito and E. L. May, J. Org. Chem., 1962, 27, 1087.
8. W. F. Michne and N. F. Albertson, J. Med. Chem., 1972, 15, 1278.
9. The stereochemistry of 2 was determined by the X-ray analysis and the data will be described in a separated paper.
10. Antagonist activity of 3·HCl to morphine analgesia was evaluated. ED_{50} value of morphine alone (6.9 mg/kg, mice tail pinch method, s.c.) was shifted to 15.0 mg/kg by the simultaneous application of 1.0 mg/kg of 3·HCl.

Received, 3rd June, 1985